Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma

Haoyu Ruan; Ting Wang; Chen Yang; Guangzhi Jin; Dishui Gu; Xuan Deng; Cun Wang; Wenxin Qin; Haojie Jin

doi:10.1038/srep32421

Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma

Sci Rep. 2016 Sep 1:6:32421. doi: 10.1038/srep32421.

Authors

Haoyu Ruan¹, Ting Wang¹, Chen Yang¹, Guangzhi Jin², Dishui Gu¹, Xuan Deng¹, Cun Wang¹, Wenxin Qin¹, Haojie Jin¹

Affiliations

¹ State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

Abstract

Longevity assurance homolog 2 of yeast LAG1 (LASS2) has been reported to act as an important tumor suppressor in the development of human cancers. However, little is known about the prognostic value of LASS2 in hepatocellular carcinoma (HCC) . In the present study, we analyzed correlation between LASS2 and TGF-β1 levels, and evaluated their prognostic values in HCC patients. We first analyzed the expression of LASS2 and TGF-β1 in two independent cohorts (test cohort: 184 HCC patients; validation cohort: 118 HCC patients) using immunohistochemistry (IHC). Kaplan-Meier survival and Cox regression analyses were executed to evaluate the prognosis of HCC. The results of IHC analysis revealed a positive correlation between the expression of LASS2 and TGF-β1. HCC Patients with low expression of LASS2 and TGF-β1 had shorter overall survival (OS) and time to recurrence (TTR) than patients with high expression of LASS2 and TGF-β1. Furthermore, combination of LASS2 and TGF-β1 was an independent and significant risk factor for OS and TTR. In conclusion, low expression of LASS2 and TGF-β1 contributes to the aggressiveness and poor prognosis of HCC, and may represent a novel prognostic biomarker for HCC patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / metabolism
Carcinoma, Hepatocellular / diagnosis
Carcinoma, Hepatocellular / genetics*
Carcinoma, Hepatocellular / metabolism
Carcinoma, Hepatocellular / mortality
Cohort Studies
Female
Gene Expression Regulation, Neoplastic*
Humans
Immunohistochemistry
Liver Neoplasms / diagnosis
Liver Neoplasms / genetics*
Liver Neoplasms / metabolism
Liver Neoplasms / mortality
Male
Membrane Proteins / genetics*
Membrane Proteins / metabolism
Middle Aged
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / genetics*
Neoplasm Recurrence, Local / metabolism
Neoplasm Recurrence, Local / mortality
Prognosis
Risk Factors
Signal Transduction
Sphingosine N-Acyltransferase / genetics*
Sphingosine N-Acyltransferase / metabolism
Survival Analysis
Transforming Growth Factor beta1 / genetics*
Transforming Growth Factor beta1 / metabolism
Tumor Suppressor Proteins / genetics*
Tumor Suppressor Proteins / metabolism

Substances

Biomarkers, Tumor
Membrane Proteins
TGFB1 protein, human
Transforming Growth Factor beta1
Tumor Suppressor Proteins
CERS2 protein, human
Sphingosine N-Acyltransferase